Trial Profile
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2014
Price :
$35
*
At a glance
- Drugs Squalamine (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genaera Corporation
- 02 Apr 2014 New trial record